Hormone receptor‐expressing (HR+) BC is the most frequent type of BC for which endocrine therapy (ET) is the standard treatment, recommended for 5 years or more, to prevent the development of metastatic disease, loco‐regional recurrences, and contralateral tumors [5]. Here, NR4A1 is linked to breast cancer.